Evaluation of demographic and rare clinical characteristics of patients with thoracic carcinoid tumor in Razi and Aria Hospitals of Rasht during 2006-2016

Manouchehr Aghajanzadeh, Mohammad Reza Asgary, Ali Alavi Fomani, Alireza Jafarinegad, Azita Tangestaninejad, Hossein Hosseinizadeh Asli, Maryam Ahmad Khan beige, Rastin Hosseinizadeh Asli, Mohammad Madi Asgari

Inflammatory Lung Diseases Research Center, Department of Internal Medicine, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

ABSTRACT

Introduction: Carcinoid tumors are malignant neoplasms of neuroendocrine cells. This study tended to evaluate the demographic and rare clinical characteristics of patients with thoracic carcinoid tumor during 2006-2016 at Razi and Aria Hospitals in Rasht.

Materials and Methods: The present study was performed on records of 43 patients with lung carcinoid tumors referred to Razi and Aria Hospitals of Rasht during 2006-2016. Information on age, gender, rare clinical symptoms, smoking history, diagnosis tools, treatment, and outcome were analyzed.

Results: Of 43 patients treated with definitive diagnosis of carcinoid tumor pathology, 31 patients had typic carcinoid tumor and 12 patients with atypic carcinoma (mean age 43.14 ± 15.16 years). The most common clinical symptom was cough and hemoptysis. Two cases presented with cushing syndrome. The most common diagnostic method in this study was simultaneous use of both CT scans and bronchoscopy. In 95.3% of cases, the tumor was pulmonary and in 4.7% of cases, it was extrapulmonary. Right lower lobe was the most common site of tumors and most of the surgeries used were lobectomy.

Conclusion: This study showed that the most common clinical sign of thoracic carcinoid is cough and the tumor is pulmonary in 95.3% of cases. Right lower lobe was the most common site of tumors and most of the surgeries used were lobectomy. Outcome was good.

Keywords: Carcinoid tumor, chest, demographic

Introduction

The incidence of neuroendocrine tumors has been increasing in recent years.[1] Neuroendocrine tumors are uncommon, slow-growing neoplasms with incidence of 1-2 in 100,000 patients.[2-4] Carcinoid tumors were described first in 1882. In 1930, it was classified and designated as bronchial adenoma.[5] Carcinoid tumors originate from neuroendocrine cells and are slow-growing tumors.[6] In terms of embryology, carcinoid tumor originate from any part of the foregut, such as stomach, duodenum, gall bladder, pancreas and from trachea, bronchus, and lung.[6] Limited information is currently available on long-term clinical prognosis and prognostic factors of these tumors.[7] The use of newer diagnostic techniques, including biochemical, immunohistochemical, and molecular methods,
has had a significant effect on identification, diversity of histopathological species, clinical behavior, and prognosis of these tumors. The new WHO classification, considering the biological behavior of tumors based on tumor location and differentiation rate, is useful both clinically and in terms of prognostic factors. Neuroendocrine carcinoma is a neoplasm of the neuroendocrine system, which contains organs in which amine precursor uptake and decarboxylation (APUD) cells are uncommon. Neuroendocrine carcinoma has been found in a wide range of organs in humans and animals. In animals, this carcinoma has been reported in the intestines, liver, bile ducts, lungs, gall bladder, esophagus, nasal cavity, and skin, most of which are highly invasive. In the human body, the most common site of neuroendocrine carcinoma is the gastrointestinal tract and the lung. Bronchopulmonary carcinoid tumor comprises 1 to 2% of all malignant lung tumors. Surgery is the most effective treatment of all types of lung carcinoid tumors. Chemotherapy and radiotherapy have no effective role in treatment of these tumors, although they are used in treatment of advanced carcinoid tumors. Surgical treatment is not recommended in cases where the tumor is locally advanced and encounters adjacent vital structures. Therefore, demographic and clinical characteristics can be helpful in diagnosis, treatment, and evaluation of prognosis.

Materials and Methods

Population and sampling
Participants included all patients with lung carcinoid tumors who were treated during 2006-2016 at Razi and Aria Hospitals of Rasht (Guilan University of Medical Sciences). Pathologic responses were obtained from Razi Laboratory, Sina Laboratory, and Dr. Ashtiani Laboratory. In this study, all patients with lung carcinoid tumors who had undergone surgical treatment for the past 11 years (2006-2016) were evaluated.

Methods
In this retrospective cross-sectional study, all patients with lung carcinoid tumor who were treated during 2006-2016 at Razi and Aria Hospitals of Rasht (Guilan University of Medical Sciences) and in collaboration with the Sina, Razi, and Dr. Ashtiani’s laboratories were examined. In this study, the exact type of tumor and all the information about thoracic carcinoid tumor is based on pathology. The studied data included age, gender, tumor location, metastatic status, tumor location, site of involvement, history of smoking, type of tumor (typic or atypic), resection type, diagnostic methods, signs, and symptoms of the disease. Forms were designed as checklists to extract information. Non-probabilistic convenient sampling was used.

Data analysis
The collected data were inserted into SPSS software version 22. Descriptive indices including frequency, frequency percentage, mean, and standard deviation were used to report descriptive data. Independent t-test was used to determine the relationship between patient gender and age (p < 0.05).

Ethical considerations
The information obtained from the patient files will be kept confidential and the results will be published in full in the form of information from the studied group and the results will be presented without mentioning their names and personal details.

Results

Gender and age
Of 43 patients (39.5%), 17 were male and 26 (60.5%) were female. The mean age of the patients was 43.14 ± 15.16 years. Maximum and minimum age of patients were 78 and 17 years, respectively. After dividing the age of the patients into 10-year groups, the majority of patients were in the age range of 31-40 years. The mean age of males was 44.82 ± 14.12 years and the mean age of females was 42.03 ± 15.97 years and there was no significant difference between males and females in terms of age (p = 0.562).

Diagnostic methods
The most common diagnostic method in this study was simultaneous use of CT scan and bronchoscopy with 27 cases (62.8%), followed by bronchoscopy with nine cases (20.9%) and CT scan with seven cases (16.3%) [Figure 1].

Smoking and symptoms
In this study, nine patients (20.9%) were smokers, 32.4% (74.4%) had no history of smoking and (4.7%) had quit smoking [Figure 2]. The most common symptoms observed in this study were cough, hemoptysis, pneumonia, shortness of breath, fever, chest pain, sputum, and Cushing's syndrome [Table 1].

Location, most affected site, and type of tumor
Forty-one (95.3%) cases had pulmonary tumor and 2 (4.7%) cases had extrapulmonary tumor. The most frequent lung involvement was right lower lobe with 25.6% [Figure 3]. Right lower lobe was the most frequently observed tumor site (25.6%). There was no significant relationship between smoking and tumor site (p = 0.511) [Table 2]. In 31 cases (72.1%), the tumor was typic and 12 cases (27.9%) had atypic tumor. There was no significant relationship between type of tumor and age (p = 0.127). There

![Figure 1: Frequency of diagnostic methods](diagram.png)

**Figure 1:** Frequency of diagnostic methods
was no significant relationship between smoking and type of tumor ($p = 0.687$).

**Performed surgeries**

The most common surgeries included lobectomy (26 cases), followed by segmental resection, pneumonectomy, sleeve resection, lung wedge resection, and bilobectomy [Table 3].

In this study, 43 patients were studied, with three cases of recurrence in the atypic group which occurred within one and five years and one case in the typic group in year 8 undergoing surgical treatment of wedge resection. Ten-year survival was observed in the typic form (90%) and in atypic type (60-70%). In recurrent cases, lobectomy or pneumonectomy was performed. There was one case of hospital mortality that occurred during surgery due to tumor aspiration and removal during manipulation, and the patient was not anesthetized with double lumen. The observed complication was atelectasis in four patients who recovered with physiotherapy. Air leaks were also observed in two patients who recovered spontaneously. The average length of hospital stay was six days.

**Discussion**

Lung carcinoid tumor originates from a specific group of bronchial epithelial cells that have neuroendocrine activity. Carcinoid tumors, despite their slow growth and slow progression, are considered malignant because they have the ability to invade surrounding tissues locally and metastases.[18]

The preferred treatment for all types of carcinoid tumors is surgery, since chemotherapy and radiotherapy have little effect in treatment of this disease.[18] Of 43 patients studied, 17 (39.5%) were male and 26 (60.5%) were female. The mean age of the patients was 43.14 ± 15.16 years. Maximum and minimum age of patients were 78 and 17 years, respectively. The majority of people were in the age range of 31-40 years. There was no significant difference between males and females in terms of age. The most common diagnostic method used in this study was simultaneous use of CT scan and bronchoscopy, followed by bronchoscopy and CT scan. Moreover, 20.9% of patients were smokers and most of the symptoms were cough, hemoptysis, pneumonia, shortness of breath, fever, chest pain, sputum, and Cushing’s syndrome, respectively. In 95.3% of the cases, the tumor was pulmonary and in 4.7% of the cases it was extrapulmonary. The most frequent lung involvement was in the right lower lobe with 25.6%. In 72.1% of cases, the tumor was typic and in 27.9%, it was atypic. There was no significant relationship between tumor type and age. The most common surgeries included lobectomy (26 cases), followed by segmental resection, pneumonectomy, sleeve resection, lung wedge resection, and bilobectomy resection.
Arab et al\(^{[20]}\) conducted a study in 2007 to evaluate clinical features, diagnostic, and therapeutic practices on lung carcinoid tumors at Masih Daneshvari Hospital within 11 years (1997-2007). There was no statistically significant difference between male and female patients, which is consistent with the results of this study. The history of smoking in 14 patients (19.2%) was consistent with the results of our study. The most common clinical symptoms were hemoptysis and cough, which is consistent with the results of our study. The final pathologic response was typical carcinoid in 81.8% and atypical carcinoid in 12.1% and tumor was not found in 6.1%. Concerning the prevalence of typical carcinoid, it is consistent with our results. Herde et al\(^{[21]}\) evaluated the clinical and radiologic symptoms and treatment of patients with carcinoid tumor on records of 21 patients with lung carcinoid. Of 21 patients treated with definitive diagnosis of carcinoid tumor pathology, 19 patients had typical carcinoid tumor and 2 patients had atypical carcinoid, which is consistent with our results. As Klöppel G et al\(^{[29]}\) reported, the right bronchus was most frequently involved. This is in contrast to the results reported by Fink et al\(^{[22]}\) and Ronchon et al\(^{[23]}\) who introduced the right lobe, or Okike et al\(^{[24]}\) who reported the lower right and left lobes as the sites most affected. Surgery was the most common treatment in our study and lobectomy was performed more than pneumonectomy, which was similar to other studies.\(^{[25]-[28]}\) Morandi et al\(^{[29]}\) reported in 2006 that carcinoid tumors had an equal prevalence of gender and appeared to occur in women at a younger age than men (although this difference was not statistically significant). There was a history of smoking in 30% of patients with typical carcinoid and 60-80% of patients with atypical carcinoid, but there was no statistically significant difference, which is consistent with our results. The significance of diagnosing this tumor lesion is that: First, due to slow tumor growth, nonspecific symptoms including cough, shortness of breath, and wheezing, it is sometimes confused with pulmonary disease and treated with inhaled and systemic bronchodilators. Second, carcinoid tumor treatment is complete resection of the tumor through surgery. Third, recurrence of the lesion is very low with timely surgical treatment. Therefore, this disease should be considered in patients with chronic cough, recurrent pneumonia, localized or even diffuse pneumonia, stridor, and hemoptysis.\(^{[21],[30]}\)

**Conclusion**

According to results of the present study, the majority of people were in the age range of 31-40 years. There was no statistically significant difference between males and females in terms of age. The most common diagnostic method used in this study was simultaneous use of CT scans and bronchoscopy. The most common symptoms observed in this study were cough and hemoptysis. In 95.3% of the cases, the tumor was pulmonary and in 4.7% of the cases, it was extrapulmonary and the most frequent lung involvement was in the right lower lobe. In 72.1% of the cases, it was typical and in 27.9%, it was atypical. There was no significant relationship between tumor type and age. The most common surgery was lobectomy (n = 26), followed by segmental resection, pneumonectomy, sleeve resection, lung wedge resection, and bilobectomy resection.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Oulett LF, Reid R, et al. Consensus recommendation for the diagnosis and management of well differentiated gastroenteropancreatic neuroendocrine tumours. Curr Oncol 2010;17:49-64.
2. Durante C, Boukeris H, Dromain C, Duvillard P, Leboulleux S, Elias D, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well differentiated endocrine carcinoma. Endocr Relat Cancer 2009;16:585-97.
3. Rosennau J, Bahr MJ, Wasielewski R, Mengel M, Schmidt HH, Nashan B, et al. Ki 67, as a prognostic indicator of long term outcome after liver transplantation for metastatic neuroendocrine tumour. Clin Transplant 2002;7:386-94.
4. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastasis: Does aggressive management improve survival? Ann Surg 2005:241:776.
5. Jochmanova I, Abcede AMT, Guerrero RJS, Malong CLP, Wesley R, Huynh T, et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. J Cancer Res Clin Oncol 2020;146:1051-63.
6. Marchevsky AM. Neuro endocrine tumors of the lung. In: Marchevsky AM, editor. Surgical Pathology of Lung Neoplasms. New York: Marcel Dekker; 1990. p. 246-88.
7. Modlin IM, Sandor A. Analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-29.
8. Sun TY, Hwang G, Pancirer D, Hornbacker K, Codima A, Lui NS, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: Clinical characteristics and progression to carcinoid tumour. Eur Respir J 2022;59:2101058. doi: 10.1183/13993003.01058-2021.
9. Klöppel G, Perren A, Heitz P. The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann N Y Acad Sci 2004;1014:13-27.
10. Kulve MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858-68.
11. Pantnaik AK, Liu SK, Johnson GF. Feline intestinal adenocarcinoma: A clinicopathologic study of 22 cases. Vet Pathol 1976;13:1-10.
12. Arnold R. Diagnosis and management of neuroendocrine tumors. United Eur Gastroenterol Week 2001;8:1-12.
13. Pantnaik AK. Canine and feline nasal and paranasal neoplasms. In: Reznik G, editor. Morphology and Origin of Nasal Tumor in Animals and Man. 2nd ed, vol 2. Boca Raton, FL: CRC Press; 1983. p. 199-228.
14. Pantnaik AK. A morphologic and immunity to chemical study of hepatic neoplasms in cats. Vet Pathol 1992;29:405-15.
15. Pantinaik AK, Lie barman PH, Hurvitz AJ, Johnen GF. Canine hepatic carcinoids. Vet Pathol 1981;18:445-53.
16. Al-khafaji B, Noffsinger AE, Miller MA, Devoe G, Stemmermann NU, Fenelglio-presser C. Immunohistologic analysis of GI and pulmonary carcinoid tumors. Hum Pathol 1998;29:992-9.
17. Naalsund A, Rostad H, Strom EH, Lund MB, Strand TE. Carcinoid lung tumors-incidence, treatment and outcomes: A population-based study. Eur J Cardiothorac Surg 2011;39:565-9.
18. Srirajaskanthan R, Toumpanakis C, Karpidakis A, Marelli L, Quigley AM, Dusmet M, et al. Surgical management and palliative treatment in bronchial neuroendocrine tumors: A clinical study of 45 patients. Lung Cancer 2009;65:68-73.
19. John R. Roberts: Other lung malignancy. Sabiston and Spencer Surgery of the Chest. 7th ed, vol 1. Chapter 22. Elsevier Inc.; 2005.
20. Darling G, Robert J. Ginsberg: Carcinoid tumors. Shields General Thoracic Surgery. 6th ed, vol II, Chapter 116. Lippincott Williams and Wilkins; 2005.
21. Herde RF, Kokeny KE, Reedy CB, Akerley WL, Hu N, Boltax JP, et al. Primary pulmonary carcinoid tumor: A long-term single institution experience/Primary pulmonary carcinoid tumor. Am J Clin Oncol 2018;41:24-9.
22. Gould WE, Warren WH. Epithelial Neoplasms of the Lung, Thoracic Oncology. 2nd ed. Chapter 4. W. B. Sanders Company. 4. Thunnissen: Beasley MB; 1995.
23. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, et al. Pulmonary atypical carcinoid: Predictors of survival in 106 cases. Hum Pathol 2000;31:1255-65.
24. Gomez A, Malaon R, Lopez L, Canes R, Jaca C, et al. Bronchial carcinoid tumors. Analysis of 41 cases. Rev Clin Esp 2004;204:202-3.
25. Dureux M, Baudin E, Schlumberger M. Treatment strategy of neuroendocrine tumors. Rev Prat 2002;52:290-6.
26. Filosso PL, Rena O, Donati G, Casadio C, Ruffini E, Papalia E, et al. Bronchial carcinoid tumors: Surgical management and long-term outcome. J Thorac Cardiovasc Surg 2002;123:303-9.
27. Divisi D, Crisci R. Carcinoid tumors of the lung and multimodal therapy. Thorac Cardiovasc Surg 2005;53:168-72.
28. Canizares MA, Garcia-Fontan EM, Rivo JE, Gonzalez-Piñeiro A. Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumor. Clin Transl Oncol 2005;7:216-8.
29. Hage R, dela Riviere AB, Selendrijck CA, van den Bosch JM. Update in pulmonary carcinoid tumors. Ann Surg Oncol 2003;10:697-704.
30. McMullan DM, Wood DE. Pulmonary carcinoid tumors. Semin Thorac Cardiovasc Surg 2003;15:289-300.